Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02124746 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
A Phase 2 study, sponsored by Sierra Oncology LLC - a GSK company.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT02124746 is a Phase 2 study that has completed, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 87 participants.
The verdict
NCT02124746, a Phase 2 study, has completed, sponsored by Sierra Oncology LLC - a GSK company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF), polycythemia vera (PV), or essential thrombocythemia (ET), who have tolerated and achieved stable disease or better with momelotinib treatment while enrolled in a previous clinical trial.
Interventions
- DRUG Momelotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2014-04-30 |
| Est. Completion | 2018-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02124746
The ClinicalTrials.gov registry entry for NCT02124746 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sierra Oncology LLC - a GSK company, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Momelotinib is the first listed.
NCT02124746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02124746 about?
NCT02124746 is a clinical study titled "Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia". This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF), polycythemia vera (PV),...
What is the current status of trial NCT02124746?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2014-04-30. Estimated completion is 2018-12-06.
What interventions are being tested in trial NCT02124746?
The interventions under investigation include: Momelotinib (DRUG).
Who is sponsoring clinical trial NCT02124746?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.